Physician

Michael Diaz, MD

According to 2025 Medicare claims, Michael Diaz, MD (NPI: 1871574186) practices hematology/oncology in the St. Petersburg-Clearwater-Largo, FL market, with the plurality of this provider's patient population coming from Pinellas, FL. This provider's primary affiliated billing organization is FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (NPI: 1760590962; TIN: 65-0825133) and primary practice location at 33705-1420.

Diaz's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 552 traditional Medicare patients, billed 235,025 HCPCS/CPT codes, and received $2,178,621 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 723 prescription claims across 246 beneficiaries totaling $1,445,920 in drug costs, led by Revlimid (Lenalidomide). 2020 DME data shows 12 claims. Open Payments data shows 175 records totaling $4,403. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs did not follow a clear longitudinal pattern. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	720	225,617	$1,520,412
2016	790	217,515	$1,742,064
2017	874	190,646	$2,325,272
2018	951	191,331	$2,333,440
2019	1,024	243,994	$2,110,489
2020	944	289,099	$3,128,954
2021	826	302,391	$3,817,340
2022	716	255,159	$3,067,120
2023	559	224,332	$2,459,190
2024	552	235,025	$2,178,621

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	175	913	$832,295
2016	195	1,106	$1,413,357
2017	217	1,310	$1,706,130
2018	188	1,079	$1,679,867
2019	193	954	$1,772,531
2020	193	1,014	$2,259,392
2021	226	1,139	$2,269,916
2022	214	951	$1,837,980
2023	232	893	$1,610,128
2024	246	723	$1,445,920

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	250	$43,779
2016	N/R	166	$10,440
2017	N/R	39	$3,629
2018	N/R	23	$3,747
2019	N/R	29	$5,767
2020	N/R	12	$1,971
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	311	917	$93
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	144	195	$66
96372	Injection of drug or substance under skin or into muscle	157	638	$10
36415	Insertion of needle into vein for collection of blood sample	418	1,183	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	422	1,296	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	24	672	$304,648
Promacta	Eltrombopag Olamine	14	420	$186,874
Brukinsa	Zanubrutinib	11	330	$103,814
Eliquis	Apixaban	48	2,655	$50,863
Xarelto	Rivaroxaban	13	690	$12,240

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	175	$4,403	PFIZER INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Michael Diaz, MD?

Tedicare shows public-source Medicare data for Michael Diaz, MD (NPI 1871574186), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Michael Diaz, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Michael Diaz, MD?

Michael Diaz, MD is linked to FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (billing NPI 1760590962) in the available physician profile data.

Does Michael Diaz, MD have Open Payments data?

Michael Diaz, MD has 175 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.